| Virksomhedsstatus | | NORMAL. |
| Sidst opdateret den 08.04.2021 og
angivet som gældende fra 07.04.2021 (1117
dage). |
Ingen historik.
| Branche | | Ikke-finansielle holdingselskaber (642020). |
| Sidst opdateret den 08.04.2021 og
angivet som gældende fra 07.04.2021 (1117
dage). |
Ingen historik.
| Revisionfravalgt | | false. |
| Sidst opdateret den 08.04.2021 og
angivet som gældende fra 07.04.2021 (1117
dage). |
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
| Navne | | Drug Development Consulting Holding ApS. |
| Sidst opdateret den 08.04.2021 og
angivet som gældende fra 07.04.2021 (1117
dage). |
Ingen historik.
| Tegningsregel | | Selskabet tegnes af to bestyrelsesmedlemmer i forening. |
| Sidst opdateret den 17.05.2021 og
angivet som gældende fra 17.05.2021 (1077
dage). |
| Fortolkning
(1 tegningsmulighed)
| | 2 bestyrelsesmedlemmer + |
| Historik | Start | Stop |
|---|
| Selskabet tegnes af to bestyrelsesmedlemmer i forening | 17.05.2021 | |
| Selskabet tegnes af direktøren | 07.04.2021 | 16.05.2021 |
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:EY Godkendt Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:30700228
Beskrivelse af revisor:State Authorised Public Accountant
Virksomhedens regnskabsklasse:Regnskabsklasse C, mellemstor virksomhed
Grundlag for konklusion (revision):Basis for opinionWe conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the consolidated financial statements and the parent company financial statements" (hereinafter collectively referred to as "the financial statements") section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Konklusion (revision):OpinionWe have audited the consolidated financial statements and the parent company financial statements of Drug Development Consulting Holding ApS for the financial year January 1 – 31 December 2022, which comprise income statement, balance sheet, statement of changes in equity and notes, including accounting policies, for the Group and the Parent Company, and a consolidated cash flow statement. The consolidated financial statements and the parent company financial statements are prepared in accordance with the Danish Financial Statements Act. In our opinion, the consolidated financial statements and the parent company financial statements give a true and fair view of the financial position of the Group and the Parent Company at 31 December 2022 and of the results of the Group's and the Parent Company's operations as well as the consolidated cash flows for the financial year 1 January – 31 December 2022 in accordance with the Danish Financial Statements Act. Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the Management's review.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
LoginOpret gratis brugere-conomic integration